Parkinson's disease, dopaminergic drugs and the plant world

被引:10
作者
Kempster, Peter [1 ,2 ]
Ma, Andrew [1 ]
机构
[1] Monash Med Ctr, Neurosci Dept, Clayton, Vic, Australia
[2] Monash Univ, Sch Clin Sci Med, Clayton, Vic, Australia
关键词
Parkinson's disease; plants; dopamine; levodopa; phytochemicals; L-DOPA; LEVODOPA THERAPY; MUCUNA-PRURIENS; RESERPINE; APOMORPHINE; SEROTONIN; BROMOCRIPTINE; ACCUMULATION; PROLACTIN; REDUCTION;
D O I
10.3389/fphar.2022.970714
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A large proportion of drugs used for the treatment of neurological disorders relate to naturally occurring compounds, many of which are plant alkaloids. This is particularly true of Parkinson's disease (PD). The pharmacopoeia of PD has strong botanical origins, while major discoveries about the neurochemistry of the basal ganglia came from the study of phytochemicals. This article narrates the development of pharmacotherapy for PD in terms of historically important plant-derived substances & mdash;tropane and hamala alkaloids, reserpine, levodopa, apomorphine, and ergoline dopamine receptor agonists. Alkaloids are nitrogen-containing secondary metabolic products that tend to be biologically active. They appear to be involved in plants' adaptation to herbivorous animals, though their exact purpose and the ways in which they work are uncertain. A sizable group of alkaloids influence animal dopaminergic systems, highlighting a key biological relationship. While animals must acquire the energy that plants harness, plants need to engage with the animal attribute that they lack & mdash;movement & mdash;in order to maximize their reproductive fitness. Neuroactive flowering plant compounds have been interacting with vertebrate and invertebrate motor systems for 100 million years. A deep evolutionary connection helps to explain why the pharmacological treatment of PD is imprinted with the power of these mysterious botanical chemicals.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson's disease
    Devos, David
    Defebvre, L.
    Bordet, R.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 (04) : 407 - 421
  • [2] Dopaminergic modulation of emotional conflict in Parkinson's disease
    Fleury, Vanessa
    Cousin, Emilie
    Czernecki, Virginie
    Schmitt, Emmanuelle
    Lhommee, Eugenie
    Poncet, Antoine
    Fraix, Valerie
    Tropres, Irene
    Pollak, Pierre
    Krainik, Alexandre
    Krack, Paul
    FRONTIERS IN AGING NEUROSCIENCE, 2014, 6 : 1 - 31
  • [3] A study of dopaminergic sensitivity in Parkinson's disease: Comparison in ''de novo'' and levodopa-treated patients
    Llau, ME
    Durrieu, G
    Tran, MA
    Senard, JM
    Rascol, O
    Montastruc, JL
    CLINICAL NEUROPHARMACOLOGY, 1996, 19 (05) : 420 - 427
  • [4] An Approach to the Continuous Dopaminergic Stimulation in Parkinson's Disease
    Schwartz, Miguel
    Sabetay, Sergiu
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2012, 14 (03): : 175 - 179
  • [5] Dopaminergic modulation of visual-spatial working memory in Parkinson's disease
    Costa, A
    Peppe, A
    Dell'Agnello, G
    Carlesimo, GA
    Murri, L
    Bonuccelli, U
    Caltagirone, C
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2003, 15 (02) : 55 - 66
  • [6] Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics
    Cacabelos, Ramon
    Carrera, Ivan
    Martinez, Olaia
    Alejo, Ramon
    Fernandez-Novoa, Lucia
    Cacabelos, Pablo
    Corzo, Lola
    Rodriguez, Susana
    Alcaraz, Margarita
    Nebril, Laura
    Tellado, Ivan
    Cacabelos, Natalia
    Pego, Rocio
    Naidoo, Vinogran
    Carril, Juan C.
    MEDICINAL RESEARCH REVIEWS, 2021, 41 (05) : 2841 - 2886
  • [7] Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease
    Schapira, Anthony H. V.
    NEUROLOGY, 2009, 72 : S44 - S50
  • [8] Advances in non-dopaminergic treatments for Parkinson's disease
    Stayte, Sandy
    Vissel, Bryce
    FRONTIERS IN NEUROSCIENCE, 2014, 8
  • [9] Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function
    MacDonald, Alex A.
    Monchi, Oury
    Seergobin, Ken N.
    Ganjavi, Hooman
    Tamjeedi, Ruzbeh
    MacDonald, Penny A.
    MOVEMENT DISORDERS, 2013, 28 (02) : 153 - 160
  • [10] Peripheral markers of apoptosis in Parkinson's disease the effect of Dopaminergic drugs
    Blandini, F
    Mangiagalli, A
    Cosentino, M
    Marino, M
    Samuele, A
    Rasini, E
    Fancellu, R
    Martignoni, E
    Riboldazzi, G
    Calandrella, D
    Frigo, GM
    Nappi, G
    APOPTOSIS: FROM SIGNALING PATHWAYS TO THERAPEUTIC TOOLS, 2003, 1010 : 675 - 678